Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/32176
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pouwels, Koen B. | - |
dc.contributor.author | Yeğenoğlu, Selen | - |
dc.contributor.author | McIntosh, E. David | - |
dc.contributor.author | Ünal, Serhat | - |
dc.contributor.author | Postma, Maarten J. | - |
dc.date.accessioned | 2023-04-04T11:35:52Z | - |
dc.date.available | 2023-04-04T11:35:52Z | - |
dc.date.issued | 2016-09-10 | - |
dc.identifier.citation | Pouwels, K. B. vd. (2016). "Potential cost-effectiveness of RSV vaccination of infants and pregnant women in Turkey: An illustration based on Bursa data". Plos One, 11(9). | en_US |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://doi.org/10.1371/journal.pone.0163567 | - |
dc.identifier.uri | https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0163567 | - |
dc.identifier.uri | http://hdl.handle.net/11452/32176 | - |
dc.description.abstract | Background: Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in various stages. To assess whether one of these vaccines might be a future asset for national immunization programs, modeling the costs and benefits of various vaccination strategies is needed. Objectives: To evaluate the potential cost-effectiveness of RSV vaccination of infants and/or pregnant women in Turkey. Methods: A multicohort static Markov model with cycles of one month was used to compare the costeffectiveness of vaccinated cohorts versus nonvaccinated cohorts. The 2014 Turkish birth cohort was divided by twelve to construct twelve monthly birth cohorts of equal size (111,459 new-borns). Model input was based on clinical data from a multicenter prospective study from Bursa, Turkey, combined with figures from the (inter) national literature and publicly available data from the Turkish Statistical Institute (TUIK). Incremental costeffectiveness ratios (ICERs) were expressed in Turkish Lira (TL) per qualityadjusted life year (QALY) gained. Results Vaccinating infants at 2 and 4 months of age would prevent 145,802 GP visits, 8,201 hospitalizations and 48 deaths during the first year of life, corresponding to a total gain of 1650 QALYs. The discounted ICER was estimated at 51,969 TL (26,220 US $ in 2013) per QALY gained. Vaccinating both pregnant women and infants would prevent more cases, but was less attractive from a pure economic point of view with a discounted ICER of 61,653 TL (31,106 US $ in 2013) per QALY. Vaccinating only during pregnancy would result in fewer cases prevented than infant vaccination and a less favorable ICER. Conclusion: RSV vaccination of infants and/or pregnant women has the potential to be costeffective in Turkey. Although using relatively conservative assumptions, all evaluated strategies remained slightly below the threshold of 3 times the GDP per capita. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Publication Library Science | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Science & technology - other topics | en_US |
dc.subject | Respiratory-syncytial-virus | en_US |
dc.subject | United-states | en_US |
dc.subject | High-risk | en_US |
dc.subject | Infection | en_US |
dc.subject | Children | en_US |
dc.subject | Influenza | en_US |
dc.subject | Mortality | en_US |
dc.subject | Hospitalization | en_US |
dc.subject | Prophylaxis | en_US |
dc.subject | Frequency | en_US |
dc.title | Potential cost-effectiveness of RSV vaccination of infants and pregnant women in Turkey: An illustration based on Bursa data | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000384329200016 | tr_TR |
dc.identifier.scopus | 2-s2.0-84992134212 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Enfeksiyon Hastalıkları Anabilim Dalı. | tr_TR |
dc.identifier.volume | 11 | tr_TR |
dc.identifier.issue | 9 | tr_TR |
dc.relation.journal | Plos One | en_US |
dc.contributor.buuauthor | Bozdemir, Şefika Elmas | - |
dc.contributor.buuauthor | Çelebi, Solmaz | - |
dc.contributor.buuauthor | Hacımustafaoğlu, Mustafa | - |
dc.relation.collaboration | Yurt içi | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.identifier.pubmed | 27689356 | tr_TR |
dc.subject.wos | Multidisciplinary sciences | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q1 | en_US |
dc.contributor.scopusid | 36112591400 | tr_TR |
dc.contributor.scopusid | 7006095295 | tr_TR |
dc.contributor.scopusid | 6602154166 | tr_TR |
dc.subject.scopus | Palivizumab; Bronchiolitis; Human Respiratory Syncytial Virus | en_US |
dc.subject.emtree | Respiratory syncytial virus vaccine | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cohort analysis | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Cost effectiveness analysis | en_US |
dc.subject.emtree | Drug efficacy | en_US |
dc.subject.emtree | Economic evaluation | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gestation period | en_US |
dc.subject.emtree | Health care cost | en_US |
dc.subject.emtree | Health care utilization | en_US |
dc.subject.emtree | Health program | en_US |
dc.subject.emtree | Hospitalization | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human respiratory syncytial virus | en_US |
dc.subject.emtree | Immunization | en_US |
dc.subject.emtree | Infant | en_US |
dc.subject.emtree | Markov chain | en_US |
dc.subject.emtree | Pregnant woman | en_US |
dc.subject.emtree | Prospective study | en_US |
dc.subject.emtree | Quality of life | en_US |
dc.subject.emtree | Respiratory syncytial virus infection | en_US |
dc.subject.emtree | Turkey (republic) | en_US |
dc.subject.emtree | Vaccination | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Bozdemir_vd_2016.pdf | 1.27 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License